Every day, pharmacovigilance teams race against time: process thousands of adverse event reports accurately or face regulatory penalties, patient safety gaps, and reputational damage.
Enter AI-powered ICSR processing. This is a paradigm shift that promises to bring down case handling time from weeks to days while improving data quality and compliance. But here’s the catch: not all AI tools are equal, and blind automation can introduce new risks if not implemented with precision.
This guide is your road map to navigating the AI revolution in pharma vigilance. Come along to discover the truth behind ICSR processing, the bottlenecks that plague PV teams worldwide, and how machine learning, NLP and intelligent automation are revolutionising safety operations in 2026. More importantly, we’ll show where AI shines, where it doesn’t and how to use it without sacrificing the expert judgement that is the foundation of patient safety.
What is ICSR?
An ICSR is a document that contains comprehensive details about a suspected reaction to a medicinal product that occurs in an individual patient at a specific point in time. EMA reported more than 1.7 million adverse drug reaction reports submitted to EudraVigilance in 2025. About 64% originated outside the EEA.
EudraVigilance contained 29.3 million ICSRs by the end of 2024. The database held 29,317,644 ICSRs, corresponding to 16,902,323 individual cases, as of December 31, 2024.
Challenges in ICSR processing
Correct processing of ICSR is the cornerstone of pharmacovigilance. It ensures safety and regulatory compliance. But while processing ICSRs, even the most seasoned PV experts face challenges like compromised data quality and delayed submissions that usher regulatory scrutiny.
The additional challenges that occur in ICSR processing are:
- Inaccurate information
When the information received from reporters is inaccurate, it complicates the case processing. These details may be:
- Patient information
Wrong/unclear age, incorrect date of birth, conflicting age and date of birth, incorrect sex, missing patient identifiers.
- Reporter details
Missing reporter contact information, incorrect profession, incomplete qualification, duplicate reporter information.
- Suspect drug/product
Brand name instead of active ingredient, misspelt product name, incorrect strength, wrong dosage form, incorrect manufacturer.
- Indication
Incorrect or vague reason for using the product, e.g., “infection” without specifying the condition.
- Dose and administration
Incorrect dose, frequency, route, duration, or units; e.g., “10” without specifying mg, mL, or another unit.
- Adverse event
Vague descriptions such as “felt sick”, “reaction”, or “problem”; incorrect terminology; multiple events combined into one description.
- Dates
Conflicting treatment start/stop dates, event onset dates occurring before treatment, impossible dates, or missing dates.
- Outcome
Incorrect or unclear outcome such as “recovered” when the reporter actually means “recovering”.
- Seriousness information
A reporter may state an event is “serious” without providing the criterion or provide information that does not clearly support a seriousness criterion.
- Medical history
Missing relevant conditions, incorrect medical history, or unclear relationship between medical history and the reported event.
- Concomitant medications
Missing medications, incorrect names/doses, or failure to distinguish concomitant products from the suspect product.
- Dechallenge/rechallenge
Incorrect or incomplete information about whether the event improved after stopping the product or returned after restarting it.
- Causality
Reporter may state that the drug “caused” the event without providing supporting clinical information.
- Laboratory results
Missing units, incorrect reference ranges, transcription errors, or results reported without dates.
- Pregnancy information
Incorrect gestational age, missing pregnancy dates, or inconsistent information about maternal/foetal outcomes.
- Follow-up information
New information may contradict the original report without explaining what changed.
- High volume of reports
When PV teams deal with a high volume of ICSRs, especially during post-marketing surveillance, it overwhelms them. The operational challenges it causes are:
- Intake bottlenecks
Large numbers of incoming reports can overwhelm case intake and triage teams.
- Tight reporting timelines
Teams must prioritise and process cases within applicable regulatory timelines.
- Manual workload
Data entry, validation, duplicate checking, coding, narrative writing, QC, and follow-up can consume substantial reviewer time.
- Duplicate and follow-up cases
A high volume of reports can increase the effort required to identify duplicates and link follow-up information correctly.
- Regulatory differences
The regulatory requirements vary region to region. It is a global challenge.
- EU – EMA: ICSRs submitted to EudraVigilance use the ISO ICSR standard based on ICH E2B(R3), together with EU-specific business rules and terminology.
- US (FDA): Under 21 CFR 314.80, postmarketing serious and unexpected adverse drug experiences generally require expedited reporting to FDA within 15 calendar days of initial receipt.
- Japan – PMDA: Japan has its own pharmacovigilance framework and regulatory submission requirements. While Japan also implements ICH E2B(R3)-based electronic reporting, companies must account for Japan-specific requirements and processes when preparing safety reports.
What AI does in ICSR processing
AI has the potential to revolutionise the efficiency of ICSR processing. Machine learning, deep neural learning, natural language processing and AI automation can improve case processing.
Machine learning uses training and adoption of software algorithms and statistical models. While deep and neural learning is an advanced form of ML, NLP is used for assessing data, usually in unstructured form. Artificial intelligence automation is a system or tool that requires minimal human interaction.
AI can be used to automate several steps in case processing workflows like triage, data entry and case review. This expedites case processing time and curtails human workload. It can also support quality review and causality assessment by analysing the context of ADRs, comparing similar cases, and identifying relevant patterns across datasets.
AI can further assist with safety signal evaluation and risk assessment by processing large datasets and highlighting potential safety concerns that may otherwise be difficult to identify manually. However, AI-generated insights are intended to support, not replace, expert judgement. A qualified pharmacovigilance professional remains responsible for reviewing the evidence and making the final assessment and decision.
AI tools and their relevance in ICSR case processing
- Machine Learning
Several ML algorithms are used in pharmacovigilance applications.
They comprise supervised learning and unsupervised learning.
Supervised learning can support ICSR processing by learning from previously reviewed and appropriately labelled safety cases. The model is trained using historical data in which pharmacovigilance specialists have already made decisions, allowing it to recognise patterns in new incoming reports.
Unsupervised learning can help pharmacovigilance teams identify patterns, relationships, and anomalies in ICSR data without requiring every case to be manually labelled beforehand.
- Natural Language Processing
Natural Language Processing (NLP) enables AI systems to process and interpret unstructured text contained in safety reports. Since many ICSRs arrive as free-text narratives, emails, medical records, literature articles, or other documents, NLP can help extract relevant safety information and convert it into structured data for further processing.
NLP does not inherently determine whether the information is medically correct or whether an adverse event is caused by a medicinal product. Context, ambiguity, negation, abbreviations, medical terminology, and incomplete information can all affect NLP performance. Therefore, extracted information should be appropriately reviewed within the validated ICSR processing workflow.
- Artificial Intelligence Automation
Artificial Intelligence (AI) automation can help pharmacovigilance teams streamline repetitive and data-intensive activities across the ICSR lifecycle. AI can process information from emails, forms, narratives, literature, and other sources, helping teams reduce manual effort while improving consistency and processing speed.
AI automation should augment rather than replace PV professionals. Automated outputs should be appropriately validated and reviewed, particularly where medical judgement, causality assessment, seriousness assessment, or regulatory decision-making is involved.
Limitations of AI in ICSR processing
- Poor-quality input data – Missing, inaccurate, or inconsistent information in an ICSR can lead to unreliable AI outputs.
- Difficulty understanding clinical context – AI may struggle with medical abbreviations, complex narratives, negations, and ambiguous clinical information.
- False positives and false negatives – AI may incorrectly flag relevant cases or fail to identify important safety information, requiring human verification.
- Limited explainability and validation – Some AI models can be difficult to explain, validate, and monitor within a regulated pharmacovigilance environment.
- Human expertise remains essential – AI can support processing and identify patterns, but qualified PV professionals are still needed for medical assessment, causality evaluation, safety interpretation, and final decisions.
AI-powered ICSR processing: Is this the future
AI-powered ICSR is gaining strong traction; however, AI isn’t given autonomous end-to-end tracking. Rather, the concept is augmented automation with human oversight.
AI is applied to case intake and triage, information extraction, medical coding, duplicate detection & routing, and causality & signal support. Multiple organisations are seeing tangible gains when AI is embedded in real PV workflows.
It cuts down on time from days to hours, reduces cost by 65%, and, using models like GPT‑4o, shows high accuracy in extracting key clinical elements from narratives within a human-in-the-loop framework, potentially reducing review time.
So, is AI-powered ICSR the future? Yes, AI-powered ICSR processing is the operational future for most sponsors and CROs. But the mature model for the next several years is AI-first, human-verified: AI does the heavy lifting; safety physicians and PV specialists focus on complex judgement, edge cases, and final sign-off.
Are you looking for AI-powered ICSR processing? Take the first step and contact us now!